**Clinical Workstream updates - 19th April 2021**

**Contents:**

1. Summary of changes within the Green Book
2. AZ Contraindications
3. Moderna vaccine National Protocol and PGD
4. Which vaccine PHE Poster
5. JCVI new guidance for pregnant women
6. Regional collaborative
7. COVID-19 vaccine animations launched to help tackle disinformation
8. Case study: Newham Vaccination Centre outreach programme
9. **Summary of changes within the Green Book**

The Chapter 14a of the “Green Book” regarding COVID-19 – SARS-COV-2 is updated on a regular basis as new vaccines become available, knowledge increases and following feedback. The most recent version dated 13 Apr 21, contains some significant amendments which should be brought to the attention of clinical and administrative staff involved with the deployment of COVID-19 vaccination. [COVID-19: The green book, Chapter 14a](https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a). A summary of the significant changes are available for reference [here](https://future.nhs.uk/CovidVaccinations/view?objectId=26621328).

1. **AstraZeneca COVID-19 Vaccine Contraindications**

The MHRA on Thursday updated the [contraindications](https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca#clinical-particulars) for the COVID-19 Vaccine AstraZeneca; these are now:

*Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.*

*Patients with a history of heparin-induced thrombocytopenia and thrombosis (HITT or HIT type 2).*

*Patients who have experienced major venous and/or arterial thrombosis occurring with thrombocytopenia following vaccination with any COVID-19 vaccine should not receive a second dose of COVID-19 Vaccine AstraZeneca*.

To note that this condition is rare, tends to present with unusual forms of clotting and the mechanism is believed to be an idiosyncratic reaction related to an immune response to the first dose of the COVID-19 Vaccine AstraZeneca. Because of this likely immune mechanism, there is no reason to believe that individuals with a past history of clots or of certain thrombophilic conditions would be at increased risk of this very rare condition.

As a precautionary measure, administration of the COVID-19 Vaccine AstraZeneca in patients with a history of cerebral venous sinus thrombosis, or antiphospholipid syndrome should only be considered when the benefit outweighs any potential risks.

Further information can be found in the [updated chapter of the green book](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/978508/Green_book_chapter_16April2021.pdf).

Frequently Asked Questions: MHRA and JCVI guidance on COVID-19 Vaccine AstraZeneca and very rare clotting disorders are available [here](https://www.england.nhs.uk/coronavirus/publication/frequently-asked-questions-mhra-and-jcvi-guidance-on-astrazeneca-covid-19-vaccine-and-very-rare-clotting-disorders/).

Further information for healthcare professionals is also available [here.](https://www.gov.uk/government/publications/covid-19-vaccination-blood-clotting-information-for-healthcare-professionals/information-for-healthcare-professionals-on-blood-clotting-following-covid-19-vaccination)

1. **Moderna Vaccine National Protocol and PGD**

Colleagues will have seen that the Moderna COVID-19 Vaccine has been launched in specific Vaccination Centres. The National Protocol for Moderna is available here: <https://www.england.nhs.uk/coronavirus/covid-19-vaccination-programme/legal-mechanisms/national-protocols-for-covid-19-vaccines/>

The PGD is available here: <https://www.england.nhs.uk/coronavirus/covid-19-vaccination-programme/legal-mechanisms/patient-group-directions-pgds-for-covid-19-vaccines/>

A template for a PSD is also available on NHS Future [here](https://future.nhs.uk/CovidVaccinations/view?objectID=26621328).

1. **Which vaccine**

Colleagues are asked to note the updated PHE poster which includes Moderna. It is available here: [Which COVID-19 vaccine? (publishing.service.gov.uk)](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/977477/PHE_HCP_which_COVID-19_vaccine_Moderna.pdf)

1. **JCVI updated guidance on vaccinating pregnant women**

Colleagues are asked to note the updated JCVI guidance on vaccinating pregnant women [here](https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/04/c1259-jcvi-announcement-regarding-covid-19-vaccination-during-pregnancy-and-next-steps.pdf).

1. **Regional Collaborative**

The Clinical workstream is being supported by the National Improvement Team (NHSE/I) to deliver a Regional Collaborative. The aim of the collaborative is to build on what has already been achieved to help teams to continue to deliver during the next phases of the programme.

As a start and to aid the design of the Regional Collaborative we will be hosting an initial meeting on Friday 23rd April starting at 9:30 am until 12:00 noon. It will be an open forum event and will go into break out rooms to allow everyone to contribute. To help design the collaborative, we will be asking you about ideas for wider testing, to think about what issues you have faced within your area of the programme, what you think would be helpful in terms of support for future delivery of vaccines as we enter phase 2 and for phase 3. To date, some of the recurring national themes we have come across are related to supporting improvement in managing flow; innovative ideas for cohort penetration; supporting leadership within the PODs; and communication throughout the programme.

We are really keen to design a collaborative which will work for you, so to achieve this we require your support and a minimum of 5 people from your region to get their shared perspectives. We are requesting that you please share this [link](https://www.events.england.nhs.uk/events/regional-vaccination-programme-collaboration-event) and attached [poster](https://future.nhs.uk/CovidVaccinations/view?objectId=27248784) with regional, ICS and site operational / clinical leads to register for this event.

We look forward to seeing you and your team on the 23rd April 2021 to support what we hope will be a really helpful collaborative process as we move to support the vaccination of Cohorts 10-12 and beyond.

1. **COVID-19 vaccine animations launched to help tackle disinformation**

NHS England and NHS Improvement has launched a series of animations aimed at tackling disinformation about the COVID-19 vaccine. Aimed specifically at encouraging uptake in ethnic minority groups, the animations are available in 17 different languages and are suitable for use on a wide range of social media platforms. They cover key topics including vaccine safety, how it was tested, how it was developed so quickly, what is in it, and what the side effects are. Original files can be downloaded from the campaign resource centre in the form of [short clips](https://coronavirusresources.phe.gov.uk/covid-19-vaccine/resources/disinformation-eng-translations-social-cutdowns/) and also a [longer video](https://coronavirusresources.phe.gov.uk/covid-19-vaccine/resources/disinformation-eng-translations-video-content/), and the English versions are also available on [YouTube](https://www.youtube.com/user/TheNHSEngland/videos).

1. **Case Study: Newham Vaccination Outreach Service**

Read how Barts Health NHS Trust has worked with local community groups to achieve success in vaccinating their diverse population through outreach work delivered by the large-scale NHS COVID-19 Vaccination Centre Newham at ExCel London, [here](https://future.nhs.uk/CovidVaccinations/view?objectID=26621232).

**\*\*Make sure you’re signed up to our** [***NHS Futures Platform***](https://future.nhs.uk/CovidVaccinations/grouphome)**, which has all the latest information and updates from across the *National Covid Vaccination Programme.\*\****

***Kind regards***

Jennifer Dwyer

*RVOC Inbox Manager*

**SW Regional Operations Centre**

**NHS England and NHS Improvement**

*Please note days and times below are subject to change*

****

|  |  |
| --- | --- |
| **ROC: Operations Centre for COVID-19 and EU Exit** Operating hours: Weekdays 09:00 – 17:00. Closed at weekends.✉[**england.sw-incident1@nhs.net**](mailto:england.sw-incident1@nhs.net)☏  **0303 033 9980** | **RVOC: Operations Centre for COVID-19 Vaccinations** Operating hours: Monday to Sunday 08:00 – 18:00 On-call service from 18:00 – 20:00.  ✉ [**england.swcovid19-voc@nhs.net**](mailto:england.swcovid19-voc@nhs.net) |

|  |  |
| --- | --- |
| **Vaccines – Supply, ordering and delivery queries/support** | |
| **Primary Care Networks / Practices ALL supply of consumables (i.e. non-vaccine) for ALL sites** | **Unipart** - [CS@nhsvaccinesupport.com](mailto:CS@nhsvaccinesupport.com)  0800 678 1650 | 07:00 – 19:00 Monday to Sunday |
| **Hospital Hubs / Large Vaccination Centres** | Vaccine or associated products being issued by PHE: [COVID19PHEsupplies@phe.gov.uk](mailto:COVID19PHEsupplies@phe.gov.uk)  ImmForm ordering: [Helpdesk@immform.org.uk](mailto:Helpdesk@immform.org.uk)  Deliveries of ordered vaccine: [NHS.VaccineSupport@movianto.com](mailto:NHS.VaccineSupport@movianto.com)   Tel: 01234 587199 *(need ImmForm account number & postcode*)  Access to products from sites which NHSE haven’t authorised, or wanting access to additional stock: [england.spocskh@nhs.net](mailto:england.spocskh@nhs.net) |
| **IT queries** - IT hardware & 4G connectivity (for equipment provided by NHSE), NIMS & NIVS, Pinnacle & Foundry, Data & all other IT services  Covid Vaccs Help Desk: [*vaccineservicedesk@england.nhs.uk*](mailto:vaccineservicedesk@england.nhs.uk)   ☏ **0300 200 1000** | 06:00 – 22:00 Monday to Sunday (inc. bank holidays) | |